hrcak mascot   Srce   HID

Stručni rad

Administration of prostin E2 in the treatment of stomatitis as a side-effect of radiotherapy

j. Raletić-Savić ; Medicinski fakultet, Novi Sad, Institut za onkologiju, Sremsw Kamenica
A. Živanović ; Medicinski fakultet, Novi Sad, Institut za onkologiju, Sremsw Kamenica
D. Savić ; Medicinski fakultet, Novi Sad, Institut za onkologiju, Sremsw Kamenica

Puni tekst: srpski, pdf (1 MB) str. 295-301 preuzimanja: 105* citiraj
APA 6th Edition
Raletić-Savić, j., Živanović, A. i Savić, D. (1991). Primena prostina E2 u lečenju stomatitisa kao nuspojave radioterapije. Arhiv za higijenu rada i toksikologiju, 42 (3), 295-301. Preuzeto s https://hrcak.srce.hr/149236
MLA 8th Edition
Raletić-Savić, j., et al. "Primena prostina E2 u lečenju stomatitisa kao nuspojave radioterapije." Arhiv za higijenu rada i toksikologiju, vol. 42, br. 3, 1991, str. 295-301. https://hrcak.srce.hr/149236. Citirano 17.11.2019.
Chicago 17th Edition
Raletić-Savić, j., A. Živanović i D. Savić. "Primena prostina E2 u lečenju stomatitisa kao nuspojave radioterapije." Arhiv za higijenu rada i toksikologiju 42, br. 3 (1991): 295-301. https://hrcak.srce.hr/149236
Harvard
Raletić-Savić, j., Živanović, A., i Savić, D. (1991). 'Primena prostina E2 u lečenju stomatitisa kao nuspojave radioterapije', Arhiv za higijenu rada i toksikologiju, 42(3), str. 295-301. Preuzeto s: https://hrcak.srce.hr/149236 (Datum pristupa: 17.11.2019.)
Vancouver
Raletić-Savić j, Živanović A, Savić D. Primena prostina E2 u lečenju stomatitisa kao nuspojave radioterapije. Arh Hig Rada Toksikol. [Internet]. 1991 [pristupljeno 17.11.2019.];42(3):295-301. Dostupno na: https://hrcak.srce.hr/149236
IEEE
j. Raletić-Savić, A. Živanović i D. Savić, "Primena prostina E2 u lečenju stomatitisa kao nuspojave radioterapije", Arhiv za higijenu rada i toksikologiju, vol.42, br. 3, str. 295-301, 1991. [Online]. Dostupno na: https://hrcak.srce.hr/149236. [Citirano: 17.11.2019.]

Sažetak
Patients undergoing chemotherapy or radiotherapy for malignancies often develop annoying inflammation of the oral mucosa as a side-effect of cytotoxic therapy. As prostaglandins are known to be cytoprotective Prostin E2 was given to 10 patients with neoplasms of the ear, nose, pharynx or larynx, or of the maxillofacial region, who received radiotherapy. The reference group was made up of five patients with the analogous diagnosis who received the conventional therapy with Hexoral sol. One patient was not administered any therapy. The patients that were given Prostin E2 did not develop either the inflammatory process or stomatitis. In the reference group the inflammatory process appeared in two patients and lesions were noticed in one patient. Excellent results, although still preliminary, pointed out that preventive local administration of Prostin E2 was superior to the conventional therapy and thar accordingly, Prostin E2 should be regarded as the drug of choice.

Ključne riječi
cytotoxic effects of radiotherapy; ORL neoplasms; prostaglandin E2; radiostomatitis

Hrčak ID: 149236

URI
https://hrcak.srce.hr/149236

[srpski]

Posjeta: 231 *